Cardinal Health gets 'Moderate Buy' consensus with price targets rising above $245.

Cardinal Health received a consensus 'Moderate Buy' rating from 17 analysts, with most recommending a buy and an average 12-month price target of about $245.67. Recent upgrades from Barclays, Evercore, Argus, and others have pushed price targets higher, reflecting confidence in the company's strong quarterly earnings that beat expectations. Cardinal Health reported $2.63 EPS and $65.63 billion revenue for the quarter, showing significant year-over-year growth. The company also announced a quarterly dividend of $0.5107 per share, indicating steady returns for investors.